Communiqués Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Temps Différé Japan Exchange Autres places de cotation 08:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
5 829 ^JPY	+0,97 %		+4,50 %	+50,54 %

04/06	Daiichi Sankyo rachète des actions pour plus de 29 milliards de yens en mai	MT
03/06	AstraZeneca annonce que le traitement potentiel du cancer du sein réduit le risque de progression de la maladie de 38%.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Daiichi Sankyo : ASCO highlight briefing session materia	03/06	PU
Daiichi Sankyo : ASCO presentation materia	03/06	PU
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy	02/06	BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	28/05	AQ
RevolKa Signed Master Service Agreement with Daiichi Sankyo	28/05	AQ
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial	27/05	BU
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO	21/05	BU
Daiichi Sankyo : Announces Appointments of Directors(251.4KB	14/05	PU
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial	29/04	BU
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB	25/04	PU
Daiichi Sankyo : FY2023 Reference Dat	25/04	PU
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours	08/04	AQ
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB	06/04	PU
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	03/04	AQ
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB	03/04	PU
Daiichi Sankyo : Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB	02/04	PU
Daiichi Sankyo Announces Global Management Structure and CxOs	01/04	AQ
Daiichi Sankyo : Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer(190.8KB	14/03	PU
Daiichi Sankyo : Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer (200.1KB	04/03	PU
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer	04/03	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Daiichi Sankyo Co., Ltd.

Actions

4568

JP3475350009

Communiqués

Filtres